Denali Therapeutics Inc. (DNLI)

NMS – Real vaqt narxi. Valyuta: USD

18.16

-1.57 (-7.98%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

18.28

+0.12 (0.66%)

Bozordan keyin: Mar 27, 2026, 6:55 PM EDT

Kompaniya haqida

Denali Therapeutics Inc., biofarmatsevtika kompaniyasi, neyrodegenerativ va lizosomal saqlash kasalliklarini davolash uchun terapevtik vositalarni kashf etadi va ishlab chiqadi. Kompaniya periferik yallig'lanish kasalliklari uchun Eclitasertib (SAR443122/DNL758) RIPK1 inhibitörü dasturini; Parkinson kasalligi uchun BIIB122/DNL151 LRRK2 inhibitörü dasturini; frontotemporal demensiya-granulin uchun TAK-594/DNL593 dasturini; MPS IIIA (Sanfilippo sindromi A) uchun DNL126 dasturini; va MPS II (Hunter sindromi) uchun enzim o'rnini bosuvchi terapiya dasturi bo'lgan DNL310 Tividenofusp alfa dasturini ishlab chiqadi. Uning Enzyme TransportVehicle (TV) dasturlari Pompe kasalligini davolash uchun DNL952; Parkinson va Gaucher kasalliklari uchun DNL111; va Hurler sindromi (MPS I) uchun DNL622 ni o'z ichiga oladi. Kompaniyaning OTV dasturlari, shuningdek, Altsgeymer kasalligi uchun tau'ga yo'naltirilgan DNL628; va Parkinson kasalligi uchun alfa sinukleiniga yo'naltirilgan DNL422 ni o'z ichiga oladi, shuningdek, antitel TV dasturi Altsgeymer kasalligini davolash uchun Abeta'ga yo'naltirilgan DNL921 ni o'z ichiga oladi. Kompaniya ilgari SPR Pharma Inc. nomi bilan tanilgan va 2015 yil mart oyida Denali Therapeutics Inc. nomini o'zgartirgan. Denali Therapeutics Inc. 2013 yilda tashkil etilgan va uning shtab-kvartirasi Janubiy San-Frantsisko, Kaliforniyada joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Dr. Alexander O. Schuth M.D., Ph.D.	Co-Founder, CFO, COO & Secretary
Dr. Dana Andersen	Chief Technical and Manufacturing Officer
Dr. Ryan J. Watts Ph.D.	Co-Founder, President, CEO & Director
Mr. Chris Walsh J.D.	General Counsel
Mr. Joe Lewcock Ph.D.	Chief Scientific Officer
Mr. Peter Chin M.D.	Acting Chief Medical Officer & Head of Development
Ms. Cindy Dunkle	Chief People Officer